H7N9 vaccine hopes
Source: Agencies |
November 15, 2013, Friday
|
Print Edition
Print Edition
The first human tests of experimental vaccines against the deadly H7N9 strain of avian flu has produced protective antibodies in the vast majority of recipients.
Encouraging results in early-stage trials were announced by Swiss drugmaker Novartis and Novavax, a biotech company based in Rockville, Maryland.
The H7N9 strain of avian flu emerged in China last winter and there had been 45 deaths from 137 confirmed cases this year as of late October, according to the World Health Organization.
Public health experts fear the virus could come storming back this winter.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
